HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin.

AbstractPURPOSE:
Metastatic cancers of unknown primary origin are characterised by a poor prognosis, with a survival rate from diagnosis of approximately 12 months. Conventional radiological imaging allows detection of 20%-27% of primary cancers, whereas the detection rate with positron emission tomography (PET) is 24%-40%. The aim of this study was to assess the role of 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) in the identification of occult primary cancers.
MATERIALS AND METHODS:
The study population consisted of 38 consecutive patients with histologically proven metastatic disease and negative or nonconclusive conventional diagnostic procedures. All patients were studied by 18F-FDG PET performed according to the standard procedure (6 h of fasting, intravenous injection of 370 MBq 18F-FDG, and image acquisition with a PET/CT scanner for 4 min per bed position).
RESULTS:
18F-FDG-PET/CT detected the occult primary cancer in 20 cases (53%), showing higher sensitivity than that reported for any other imaging modality, including PET.
CONCLUSIONS:
The encouraging results, if validated by larger series, support the use of PET/CT in patients with carcinoma of unknown primary origin and negative conventional imaging results.
AuthorsV Ambrosini, C Nanni, D Rubello, A Moretti, G Battista, P Castellucci, M Farsad, L Rampin, G Fiorentini, R Franchi, R Canini, S Fanti
JournalLa Radiologia medica (Radiol Med) Vol. 111 Issue 8 Pg. 1146-55 (Dec 2006) ISSN: 0033-8362 [Print] Italy
PMID17171520 (Publication Type: Journal Article)
Chemical References
  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma (diagnosis, diagnostic imaging, secondary)
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Male
  • Middle Aged
  • Neoplasms, Unknown Primary (diagnosis, diagnostic imaging)
  • Positron-Emission Tomography (methods)
  • Prognosis
  • Radiopharmaceuticals
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Tomography, X-Ray Computed

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: